AU2003292136A1 - Vaccines against viruses with cationic substances as adjuvants - Google Patents

Vaccines against viruses with cationic substances as adjuvants

Info

Publication number
AU2003292136A1
AU2003292136A1 AU2003292136A AU2003292136A AU2003292136A1 AU 2003292136 A1 AU2003292136 A1 AU 2003292136A1 AU 2003292136 A AU2003292136 A AU 2003292136A AU 2003292136 A AU2003292136 A AU 2003292136A AU 2003292136 A1 AU2003292136 A1 AU 2003292136A1
Authority
AU
Australia
Prior art keywords
adjuvants
vaccines against
against viruses
cationic substances
cationic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003292136A
Inventor
Jorma Hinkula
Ulf Schroder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eurocine AB
Original Assignee
Eurocine AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eurocine AB filed Critical Eurocine AB
Publication of AU2003292136A1 publication Critical patent/AU2003292136A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
AU2003292136A 2002-11-26 2003-11-26 Vaccines against viruses with cationic substances as adjuvants Abandoned AU2003292136A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200201826 2002-11-26
DKPA200201826 2002-11-26
PCT/EP2003/013349 WO2004047861A1 (en) 2002-11-26 2003-11-26 Vaccines against viruses with cationic substances as adjuvants

Publications (1)

Publication Number Publication Date
AU2003292136A1 true AU2003292136A1 (en) 2004-06-18

Family

ID=32337943

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003292136A Abandoned AU2003292136A1 (en) 2002-11-26 2003-11-26 Vaccines against viruses with cationic substances as adjuvants

Country Status (2)

Country Link
AU (1) AU2003292136A1 (en)
WO (1) WO2004047861A1 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1297090B1 (en) * 1997-12-01 1999-08-03 Barbara Ensoli TAT OF HIV-1 OR ITS DERIVATIVES, ALONE OR IN COMBINATION, FOR VACCINAL, PROPHYLACTIC AND THERAPEUTIC PURPOSES, AGAINST AIDS, CANCERS AND
GB9726555D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Vaccine
WO2000011140A1 (en) * 1998-08-20 2000-03-02 The Wistar Institute Of Anatomy And Biology Methods of augmenting mucosal immunity through systemic priming and mucosal boosting
SE0100011D0 (en) * 2001-01-03 2001-01-03 Eurocine Ab Karolinska Inst Sc Virus vaccine formulation
CA2458995C (en) * 2001-08-31 2013-04-30 Chiron Corporation Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof

Also Published As

Publication number Publication date
WO2004047861A1 (en) 2004-06-10

Similar Documents

Publication Publication Date Title
AU2003239932A1 (en) Tetravalent dengue vaccines
EP1603590A4 (en) Influenza virus vaccine
AU2002951692A0 (en) Improvements in or relating to vaccines
GB0213622D0 (en) Vaccine Corporation
HUS1500047I1 (en) Vaccine against the nile fever virus
HK1083597A1 (en) Avian E. coli vaccine for the protection against colibacillosis
AU2002254558A1 (en) Novel vaccine
AU2003212369A1 (en) Improvements in vaccination
AU2003206862A1 (en) Hepatitis b vaccines
EP1572918A3 (en) Synthetic glyco-lipo-peptides as vaccines
AU2003301850A1 (en) Hiv vaccine
AU2002307971A1 (en) Vaccine against the nile fever virus
AU2003285320A1 (en) Vaccine
AU2005279590A1 (en) Vaccine composition against hepatitis C virus
AU2003289603A1 (en) Tumor vaccine
AU2003249282A1 (en) Glanders/meliodosis vaccines
AU2002236065A1 (en) Papillomavirus vaccines
AU2003237701A1 (en) Vaccines
AU2002342949A1 (en) Vaccine composition comprising at least two valences, one with enhanced adjuvant and not the other
AU2003292136A1 (en) Vaccines against viruses with cationic substances as adjuvants
AU4957800A (en) Vaccine against isa virus
AU2003273035A1 (en) Gene vaccine
AU2003900767A0 (en) Idiotypic vaccine
AU2002314274A1 (en) Vaccination against the feline immunodeficiency virus
AU2002347346A1 (en) Dna vaccine

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase